One source of relief for moderate to severe acute pain
NUCYNTA®, designed as a next-generation short-acting opioid, offers the same unique, active molecule as NUCYNTA® ER (tapentadol) extended-release tablets, CII

Powerful Efficacy



Efficacy chart (thumbnail)

See phase 3 data demonstrating the strength of NUCYNTA® for patients with moderate to severe acute pain.

LEARN MORE

BROAD MANAGED
CARE ACCESS



Co-pay card thumbnail

NUCYNTA® offers confidence of access and low out-of-pocket costs for your patients.

LEARN MORE